Immunovant (IMVT) Total Liabilities (2018 - 2026)
Immunovant's (IMVT) quarterly Total Liabilities came in at $104.4 million in Q1 2026, up 51.83% YoY from $68.8 million in Q1 2025, and up 57.6% on a QoQ basis from $66.3 million in Q4 2025.
Immunovant (IMVT) Total Liabilities (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Total Liabilities data on file, last reported at $104.4 million in Q1 2026.
- Quarterly Total Liabilities rose 51.83% year-over-year to $104.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.4 million (up 51.83% YoY) and the FY2026 annual result came in at $104.4 million, up 51.83% from the prior year.
- Total Liabilities grew to $104.4 million in Q1 2026, from $66.3 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $104.4 million in Q1 2026 to a low of $22.2 million in Q2 2022.
- A 5-year average of $52.5 million and a median of $48.6 million in 2024 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 131.72% in 2023, down 22.77% in 2023.
- Tracing IMVT's Total Liabilities over 5 years: stood at $41.6 million in 2022, then declined by 22.77% to $32.1 million in 2023, then soared by 112.81% to $68.3 million in 2024, then fell by 3.01% to $66.3 million in 2025, then soared by 57.6% to $104.4 million in 2026.
- The last three Total Liabilities figures came in at $104.4 million (Q1 2026), $66.3 million (Q4 2025), and $63.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 117.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 117.10 Mn |
| Mar 31, 2026 | 104.42 Mn |
| Dec 31, 2025 | 66.26 Mn |
| Sep 30, 2025 | 63.25 Mn |
| Jun 30, 2025 | 52.90 Mn |
| Mar 31, 2025 | 68.78 Mn |
| Dec 31, 2024 | 68.32 Mn |
| Sep 30, 2024 | 66.65 Mn |
| Jun 30, 2024 | 45.02 Mn |
| Mar 31, 2024 | 48.61 Mn |
| Dec 31, 2023 | 32.10 Mn |
| Sep 30, 2023 | 40.26 Mn |
| Jun 30, 2023 | 51.36 Mn |
| Mar 31, 2023 | 43.34 Mn |
| Dec 31, 2022 | 41.57 Mn |
| Sep 30, 2022 | 32.40 Mn |
| Jun 30, 2022 | 22.16 Mn |
| Mar 31, 2022 | 45.74 Mn |
| Dec 31, 2021 | 38.03 Mn |
| Sep 30, 2021 | 30.34 Mn |